Non-Severe Gestational Hypertension When Dual Antihypertensive Therapy Has Not Reached the Diastolic Blood Pressure Target
Clinical Scenario
Gestational hypertension — hypertension arising de novo at or after 20 weeks' gestation, in the absence of proteinuria or other features of pre-eclampsia — with non-severe blood pressure: systolic BP below 160 mmHg and diastolic BP below 110 mmHg.
Previous Treatment — Failure Condition
The preceding step added a second antihypertensive agent from a different drug class (oral methyldopa, oral labetalol, oral nifedipine, or an alternative beta-blocker) alongside the initial first-line agent. Escalation to this protocol is indicated when that dual-therapy approach has not achieved the target diastolic BP of 85 mmHg.
Next Step — Partial Overview
When non-severe gestational hypertension persists despite dual antihypertensive therapy, the structured evidence-based approach involves a decision regarding the timing and initiation of birth — the full clinical criteria, sequencing, and conditions are set out in the complete protocol.
References
DOI: 10.1016/j.preghy.2021.09.008
- Hypertension arising de novo at ≥ 20 weeks' gestation in the absence of proteinuria or other findings suggestive of pre-eclampsia
- Hypertension in pregnancy continues to be defined as a clinic sBP ≥ 140 mmHg and/or a dBP ≥ 90 mmHg, with sBP ≥ 160 mmHg and/or a dBP ≥ 110 mmHg defined as severe hypertension.
- Non-severe hypertension should be treated with the first-line agents oral methyldopa, labetalol, or nifedipine (⊕⊕⊕O/Strong).
- Women who reach 40+0 weeks should be offered delivery (⊕⊕OO/Strong)
View source ↗